Ophthalmologists find new links between Ozmpic problems and vision problems

The condition of the GLP-1 medications, such as OzemPic, may cause blindness. A new paper outside this week describes many people who have developed eye conditions shortly after starting to take heavenly drugs and similar medicines.

Ophthalmologists at the University of Utah Health and other places have published the research, which describes many cases of vision complications that may be associated with these obesity and diabetes. Medicines have been linked to three different cases of the eye, all of which can lead to blindness. But with doctors warning, cases do not prove alone that the GLP-1 medications can cause these problems, and more research is needed to understand exactly what is going on.

Other research has recently suggested that there is a link between the GLP-1 drugs such as Smolutide (the active ingredient in OzemPIC, Wegovy), Tirzepatide (Mounjaro and Zepbound) and higher risk of eye problems.

Last summer, for example, researchers at an eye specialist hospital Published A study discovered that patients who described that the poultryide was noticeably more likely to develop illegal anterior optical nerve neuropathy (NAION), a rare condition caused by the loss of blood flow to the optic nerve. Last December, Denmark Health officials The name In order for the European Union to be officially fulfilled in the possible relationship between the use of the GLP-1 and NAION, in the wake of two other studies of the Danish population who found similar results.

This last paper, Published Last month in Eye Medicine GroupIt offers a series of nine cases. Seven cases include people who have suffered from NAION after the start of the GLP-1; One person has developed papilloma, a type of optic nerve inflammation; The last advanced acute medium cord illness, a type of blood vessel damage in Al -Baqa, is the central network of retina that allows a sharp vision. In many cases, resolve the loss of people’s vision or stop exacerbating after stopping the use of the drug, although some of them kept their treatment without any permanent problems.

The researchers rush to note that these individual cases are not a smoking pistol to prove that the GLP-1 drugs cause these eye problems.

“In the study of this case chain, it was not possible to determine whether there was a causal link between these drugs and the complications of the amounts reported,” they wrote. If this causal link is present, it may also be more complicated than it seems at first glance.

All one person with the exception of one person includes a person with a history of type 2 diabetes, a condition that is constantly high in blood sugar. Researchers note that some cases of papilloma have been linked to a rapid decrease in blood sugar in people, and that they speculate that the same may be true for some NAION. In other words, the GLP-1 medications may cause at least some of these cases indirectly, by quickly reducing blood sugar, instead of any direct toxic effect of the drug itself. But there may be other players to look. Some cells in the optic nerve carry GLP-1 receptors, for example, another way to these medications is provided to harm the eye function.

Either way, the researchers say more work is needed to study this possible link. Although NAION is rare, even a little increase in the risk of this may still affect many people, due to the popularity of these drugs all over the world. The detection of the mechanisms behind this connection can lead to better care. If these cases are caused by a rapid decrease in glucose in the blood, as researchers believe, we can prevent future conditions by simply recommending a slower cycle than the GLP-1 treatment in patients at risk (GLP-1 treatment is usually provided in escalation over time ). Doctors also hope their results will enhance awareness of the possible relationship between their colleagues.

More studies are needed to test our hypothesis. Pradley Katz, an ophthalmologist at Utah John University, said. Moran, “This is an important issue for ophthalmologists, where we monitor the use of these drugs and the best we can be to communicate with our patients around them.” In a statement from the university.